Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.
Evotec SE reports developments in drug discovery and development services, integrated R&D programs and strategic partnerships with pharmaceutical, biotechnology, academic and health-focused organizations. Its updates commonly cover small-molecule, biologics and cell-therapy work; AI/ML-enabled platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling; and therapeutic programs in oncology, cardiovascular and metabolic disease, neurology, immunology and infectious disease.
Recurring news also includes Just - Evotec Biologics manufacturing and biologics-development activity, grant-funded global-health work, preclinical candidate nominations, financial results and business updates. Governance items include Supervisory Board nominations, management appointments and operating-model changes tied to the company’s global R&D and partnership infrastructure.
Evotec (NASDAQ: EVO; Frankfurt: EVT) released preliminary, unaudited figures for Q2 and the first half of 2026 and revised its full-year 2026 outlook. For H1 2026, Evotec expects Group revenues of about €300.1 million and adjusted Group EBITDA of about -€42.7 million, with liquidity around €465.6 million as of 30 June 2026.
For full-year 2026, Evotec now forecasts Group revenues of approximately €570–610 million (€595–635 million CER) and adjusted Group EBITDA of approximately -€70 to -105 million (-€60 to -90 million CER. Previous guidance was €700–780 million (€730–810 million CER) for revenues and €0–40 million (€10–50 million CER) for adjusted EBITDA.
Evotec (NASDAQ: EVO) launched J.TRAIN, a turnkey model that lets biopharma partners deploy Just – Evotec Biologics’ proprietary continuous manufacturing platform inside their own facilities. The solution combines modular cleanrooms, standard equipment and cGMP-compliant automation to support faster, lower-cost capacity expansion versus traditional fed-batch plants.
J.TRAIN targets deployment in about 18 months and can produce over 500 kg of biologic drug substance from under 10,000 sq ft, which Evotec says exceeds ten times the productivity of conventional methods while enabling flexible, multi-product manufacturing.
Evotec (NASDAQ:EVO) reported results of its Annual General Meeting 2026 held in Hamburg, Germany.
All agenda items were adopted with the required majority. Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board, and re-elected Dr. Duncan McHale and Wesley Wheeler. Weinand was appointed Chairman. 43.10% of registered share capital was represented.
Evotec (NASDAQ:EVO) appointed Rui Wang as Executive Vice President, Head of Global In Silico and AI, effective June 2, 2026. He will lead integration of computational science, data and AI across R&D, supporting drug discovery, preclinical development and Just - Evotec Biologics.
Wang previously led Data, Analytics and AI at AstraZeneca and has over 20 years of experience in bioinformatics and AI-enabled drug discovery.
Evotec (NASDAQ:EVO) placed senior unsecured convertible bonds due 2033 with an aggregate principal amount of €116.1 million. The seven-year Bonds, with an investor put after five years, carry a 2.625% coupon and will be redeemed at 110% of principal, implying a 3.882% yield.
The initial conversion price is €6.5313, a 37.5% premium to the €4.75 reference price, with an effective conversion price of about €7.1844 at maturity. Net proceeds are intended to fund Project Horizon, Evotec’s transformation program.
Evotec (NASDAQ:EVO) announced nomination of a small‑molecule preclinical development candidate (PDC) from its dermatology collaboration with Almirall on May 4, 2026. The joint team advanced from initial leads to PDC in about two years, using Evotec's AI/ML‑enhanced discovery and preclinical platforms and will support IND enabling via the INDiGO platform.
The program targets immune‑mediated inflammatory skin diseases and combines Evotec's end‑to‑end discovery capabilities with Almirall's dermatology expertise to progress the candidate toward clinical readiness.
Evotec (NASDAQ:EVO) received two Gates Foundation grants totaling $9.9 million to support tuberculosis drug discovery and translational development over 24–25 months. The awards fund AI‑enabled discovery of novel small molecules and nonclinical evaluation of advanced TB drug combinations, including Long Acting Injectables, to accelerate candidate selection and de‑risk progression to clinical testing.
Evotec (NASDAQ:EVO) nominated Dr. Wolfgang Hofmann for election as an independent Supervisory Board member and proposed expanding the Supervisory Board from six to seven members.
The company announced a cooperation agreement with key shareholder MAK Capital that includes customary voting and cooperation commitments. The AGM is scheduled for June 11, 2026.
Evotec (NASDAQ:EVO) will announce its first quarter 2026 results and provide a business update on Wednesday, May 6, 2026. A live webcast and conference call in English will start at 14:00 CEST (08:00 EDT). Registered participants receive dial-in details and slides; an on-demand replay will be available on the company website.
Evotec (NASDAQ:EVO) announced that Chief Financial Officer Paul Hitchin will step down effective April 30, 2026 for personal reasons, and that Claire Hinshelwood will become CFO effective May 1, 2026.
Ms. Hinshelwood brings 30+ years of financial leadership, including roles as Group CFO of BMI Group and Global Head of Finance Operations at Novartis. Mr. Hitchin led Evotec's financial transformation since March 1, 2025.